Q-omics provides the consensus-scored CCN4 profile across patient tissues and cancer cell-line models. CCN4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CCN4 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CCN4 RNA expression shows 19,228 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where CCN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCN4 survival associations across molecular data types. CCN4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCN4 RNA expression–survival associations across cancer types. High CCN4 expression shows unfavorable associations in KIRP, ACC, LGG, KICH, BLCA and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CCN4 RNA expression.
This table summarizes CCN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CCN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCN4 shows higher tumor expression in HNSC, LUAD, COAD, BLCA, BRCA and LUSC. The HNSC box plot shows higher CCN4 RNA expression in tumor versus normal tissue (log2 FC = +3.252, t-test p < 0.001).
This table shows molecular features associated with CCN4 in patient tissues and cancer cell lines. In patient samples, CCN4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
